Givinostat (ITF-2357) is an orally bioavailable, pan-HDAC inhibitor that blocks STAT5 phosphorylation, demonstrating antitumor effects in crlf2-rearranged BCP-ALL models. Its anti-inflammatory properties, including suppression of TNF-alpha and IL-1beta, and promotion of beta-cell survival support research in leukemia, diabetes, and arthritis, as evidenced by in vitro and in vivo studies.